AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.47
+0.16 (+0.92%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close17.31
Open17.35
Bid16.01 x 100
Ask17.50 x 2000
Day's Range17.15 - 17.50
52 Week Range10.76 - 33.67
Volume1,042,088
Avg. Volume3,307,792
Market Cap2.188B
Beta1.66
PE Ratio (TTM)N/A
EPS (TTM)-0.76
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est26.75
Trade prices are not sourced from all markets
  • Akorn Fell 6.8% on July 13, Fresenius-Akorn Merger Woes Continue
    Market Realist6 days ago

    Akorn Fell 6.8% on July 13, Fresenius-Akorn Merger Woes Continue

    On July 13, Akorn (AKRX) shares fell ~6.8% and closed at $17.91. Currently, Akorn stock is trading higher than its 50-day moving average of $15.83, while the stock is trading lower than its 200-day moving average of $21.04. According to Mats Henriksson, chief executive of a Fresenius unit, Fresenius spent two years addressing the problems with one of its plants in India.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding AKRX totaled $640 million.

  • Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session
    Zacks9 days ago

    Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session

    Akorn (AKRX) was a big mover last session, as the company saw its shares rise more than 7% on the day, amid huge volumes.

  • ACCESSWIRE9 days ago

    Today's Research Reports on Trending Tickers: Akorn and Momenta Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 13, 2018 / U.S. markets made it in the green on Thursday, pushed higher by rally in information technology and telecom stocks, covering continued uncertainty over trade ...

  • Bloomberg10 days ago

    Fresenius Had Testing Issues Similar to Akorn's, Executive Says

    A Fresenius SE executive acknowledged his company has grappled with testing problems similar to those the German healthcare company cited as a basis for pulling out of $4.3 billion deal to buy U.S. generic ...

  • Fresenius Had Testing Woes Similar to Akorn, Unit Head Says
    Bloomberg10 days ago

    Fresenius Had Testing Woes Similar to Akorn, Unit Head Says

    A Fresenius SE executive acknowledged his company has grappled with testing problems similar to those the German health-care company cited as a basis for pulling out of a $4.3 billion deal to buy U.S. generic drugmaker Akorn Inc. Mats Henriksson, chief executive of a Fresenius unit, testified Thursday that U.S. Food and Drug Administration inspectors in 2013 questioned drug-injection testing and test-result storage at one of the firm’s plants in India. It took the company two years to address those problems, Henriksson told Delaware Chancery Judge Travis Laster.

  • Execution blocked after company objects to use of its drug
    Associated Press11 days ago

    Execution blocked after company objects to use of its drug

    A twice-convicted killer who wants to die rather than spend his life in prison was about an hour from eating his final meal Wednesday when he found out a Nevada judge had indefinitely delayed his execution after a pharmaceutical company objected to the use of one of its drugs to put someone to death. Instead of carrying out what would have been the first execution in Nevada since 2006 and the first in the U.S. using an untried combination of three drugs, state officials must now reassess their options. Scott Raymond Dozier, 47, was put on suicide watch as a precaution while officials planned a psychological evaluation at the state prison in the remote northeastern city of Ely before he returns to death row.

  • Akorn CEO Says Fresenius Is Using Smear Campaign to Cancel Deal
    Bloomberg12 days ago

    Akorn CEO Says Fresenius Is Using Smear Campaign to Cancel Deal

    Akorn Inc.’s top executive complained Fresenius SE officials are unfairly smearing his firm’s reputation as the German company tries to pull out of $4.3 billion deal to to buy the generic drugmaker. Raj Rai, Akorn’s chief executive officer since 2010, told a judge Tuesday Fresenius’s claims that flaws in the company’s computer system led to fraudulent test results aren’t true. Akorn says that Fresenius is using minor mistakes to create a pretext for backing out of the the $34-per-share buyout.

  • Lax Drugmaker Computer Security Linked to Deal Cancellation
    Bloomberg12 days ago

    Lax Drugmaker Computer Security Linked to Deal Cancellation

    John Avellanet, a consultant Akorn hired in 2016 after regulators questioned its operational procedures, discovered executives had little security control over the pharma company’s computer system and that raised doubts about the integrity of its record-keeping, said Lewis Clayton, a lawyer representing Fresenius SE in a trial over the failed merger. Akorn shares fell as much as 4.6 percent, the most intraday since May 3. Fresenius officials say Akorn’s testing miscues, along with a history of operational problems that drew warnings from the U.S. Food and Drug Administration, justified canceling the $34-per-share deal.

  • Akorn Was Warned About Problems Before Merger, Executive Says
    Bloomberg13 days ago

    Akorn Was Warned About Problems Before Merger, Executive Says

    A consultant warned Akorn Inc. before its merger with Fresenius SE about production-line problems that raised questions about the integrity of data it provided to drug regulators, an Akorn executive testified as a trial over the failed $4.3 billion deal began. The consultant, hired to review procedures and operations at Akorn’s Decatur, Illinois, facility in 2016, found cameras recording drug vials coming down a line didn’t properly store pictures used to check cleanliness and safety, Kim Wasserkrug, an Akorn vice president, told Delaware Chancery Court Judge Travis Laster. Fresenius officials contend manufacturing problems at the Decatur plant and others, along with Akorn’s submission of allegedly phony data to federal regulators, are justifications for nixing the $34-per-share deal.

  • TEVA or AKRX: Which Is the Better Value Stock Right Now?
    Zacks13 days ago

    TEVA or AKRX: Which Is the Better Value Stock Right Now?

    TEVA vs. AKRX: Which Stock Is the Better Value Option?

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • ACCESSWIRE28 days ago

    Free Technical Research on Akorn and Three More Generic Drugs Equities

    WallStEquities.com has selected the following Generic Drugs stocks for review today: Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), and Allergan PLC (NYSE: AGN). Companies in the generic pharmaceuticals sector make drugs that are offered cheaper than name-brand pharmaceuticals once patents for the more expensive drugs lapse.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Akorn Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswire2 months ago

    Lawsuit for Investors in shares of Akorn, Inc. (NASDAQ: AKRX) announced by Shareholders Foundation

    SAN DIEGO, June 04, 2018-- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Akorn, Inc. shares. Investors who purchased shares of Akorn, Inc. in March 2017 ...

  • Options Traders Expect Huge Moves in Akorn (AKRX) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Akorn (AKRX) Stock

    Investors in Akorn (AKRX) need to pay close attention to the stock based on moves in the options market lately.

  • Moore Kuehn, PLLC Announces an Investigation Involving Possible Breaches of Fiduciary Duties by Officers and Directors of Akorn, Inc.
    PR Newswire2 months ago

    Moore Kuehn, PLLC Announces an Investigation Involving Possible Breaches of Fiduciary Duties by Officers and Directors of Akorn, Inc.

    NEW YORK , May 29, 2018 /PRNewswire/ -- Moore Kuehn, PLLC is investigating potential claims for breach of fiduciary duty involving the directors and officers of Akorn, Inc. (NASDAQ: AKRX ).  On February ...

  • Reuters2 months ago

    Fresenius CEO defends cancelled Akorn deal

    FRANKFURT/BERLIN, May 18 (Reuters) - Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker. "It was certainly not an easy decision, but ultimately there was only one correct course," CEO Stephan Sturm, a former investment banker and experienced dealmaker, said at Fresenius' annual shareholder meeting in Frankfurt on Friday. Sturm served as chief financial officer before taking over as CEO in 2016 and has helped build the German company into a globally diversified healthcare group through a series of multi-billion dollar deals.

  • ACCESSWIRE2 months ago

    Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration. WallStEquities.com features the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. The market for generic drugs is based on the premise that patented drugs come with a lifespan of 20 years, which begins from the phase of clinical trials.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Index (PMI) data, output in the Healthcare sector is rising.

  • Investopedia2 months ago

    Top 3 Companies Owned by Valeant

    Part of the healthcare sector, Valeant Pharmaceuticals International Inc. (NYSE: VRX), is a specialty pharmaceutical company, operating in multiple countries. Valeant manufactures and markets a large bouquet of pharmaceutical products. Primary areas of focus include eye health, dermatology, neurology and generically branded medications, including over-the-counter (OTC) drugs.

  • ACCESSWIRE2 months ago

    DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX

    NEW YORK, NY / ACCESSWIRE / May 7, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Akorn, Inc. ("Akorn") ...

  • ACCESSWIRE2 months ago

    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm

    LOS ANGELES, CA / ACCESSWIRE / May 7, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 1, 2017, and February 26, 2018, are encouraged to contact the firm before May 7, 2018, the lead plaintiff deadline.

  • ACCESSWIRE2 months ago

    FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018

    NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akorn, Inc. ("Akorn" or the "Company") (AKRX) and certain of its officers, on behalf of shareholders who purchased Akorn securities during the period between March 1, 2017 through February 26, 2018, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/akrx. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.